Stockscreener 앱 받기
128.18
0.38%
0.49
전일 마감가:
$127.69
열려 있는:
$128.32
하루 거래량:
2.14M
Relative Volume:
0.61
시가총액:
$56.49B
수익:
$9.40B
순이익/손실:
$2.65B
주가수익비율:
21.60
EPS:
5.935
순현금흐름:
$2.24B
1주 성능:
+5.01%
1개월 성능:
-11.85%
6개월 성능:
-22.50%
1년 성능:
-27.48%
1일 변동 폭
$127.75
$129.31
1주일 범위
$120.27
$129.31
52주 변동 폭
$115.25
$181.85
조에티스 Stock (ZTS) Company Profile
명칭
Zoetis Inc
전화
973-822-7000
주소
10 SYLVAN WAY, PARSIPPANY, NJ
ZTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZTS
Zoetis Inc
|
128.18 | 56.27B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.42 | 45.87B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.78 | 43.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.89 | 30.20B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
486.00 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
조에티스 Stock (ZTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-07-17 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-18 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-12 | 재확인 | Stifel | Buy |
| 2023-12-19 | 재개 | Jefferies | Buy |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-03-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-09-21 | 개시 | Atlantic Equities | Overweight |
| 2020-08-14 | 업그레이드 | Edward Jones | Hold → Buy |
| 2020-08-12 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-05-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | Raymond James | Mkt Perform |
| 2019-09-09 | 개시 | Goldman | Buy |
| 2019-07-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2019-05-03 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-04 | 업그레이드 | Stifel | Hold → Buy |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-08-22 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-08-03 | 재확인 | Stifel | Buy |
| 2018-04-19 | 재확인 | Citigroup | Buy |
| 2018-03-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-02-16 | 재확인 | Stifel | Buy |
| 2018-01-04 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
조에티스 주식(ZTS)의 최신 뉴스
Is Zoetis Inc ZOE a good long term investmentTrading Volume Trends & Big Profit Low Trading - earlytimes.in
North America Companion Animal Drugs Market Set for Rapid Growth, Demand, Scope, Size, Share, Forecast 2032 | - EIN News
European Commission approves Zoetis’ three-month OA pain therapy for dogs - Investing.com Nigeria
Zoetis (ZTS) Gains EU Approval for Lenivia in Canine Osteoarthri - GuruFocus
Zoetis receives European approval for Lenivia for osteoarthritis in dogs (ZTS:NYSE) - Seeking Alpha
Zoetis (ZTS) Gains EU Approval for Canine Osteoarthritis Therapy Lenivia - GuruFocus
European Commission approves Zoetis’ three-month OA pain therapy for dogs By Investing.com - Investing.com South Africa
Zoetis receives European Commission marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs - MarketScreener
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs - MarketScreener
Stifel Lowers Zoetis (ZTS) PT to $130, Maintains 'Hold' Due to Aggressive 2026 Revenue Outlook - Finviz
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is Zoetis Stock Underperforming the Dow? - Yahoo Finance
Stifel Lowers Zoetis (ZTS) PT to $130, Maintains ‘Hold’ Due to Aggressive 2026 Revenue Outlook - Insider Monkey
Paul Harris' Top Picks: FirstService, Zoetis & Adobe - BNN Bloomberg
Top Animal Health Stocks: Elanco Leads with Innovation, Zoetis Faces Headwinds - Investing.com Canada
Cash per share of Zoetis, Inc. Class A – MIL:1ZTS - TradingView
Keybanc Initiates Coverage of Zoetis (ZTS) with Sector Weight Recommendation - MSN
Does the Recent 30% Drop Make Zoetis a Bargain Opportunity in 2025? - Yahoo Finance
Zoetis and Surgery Partners Shares Are Soaring, What You Need To Know - Finviz
Zoetis Inc. Class A (ZTS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
ZTS (Zoetis) Issuance of Stock : $0 Mil (TTM As of Sep. 2025) - GuruFocus
Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stoc - GuruFocus
Elanco wins Overweight rating, Zoetis Sector Weight as KeyBanc reviews animal health space - Seeking Alpha
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst - Sahm
KeyBanc initiates coverage on Zoetis stock with Sector Weight rating By Investing.com - Investing.com South Africa
KeyBanc initiates coverage on Zoetis stock with Sector Weight rating - Investing.com
Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by Key - GuruFocus
Zoetis, Wrangler NFR continue partnership to strengthen equine biosecurity - Equus Magazine
A Look Into Zoetis Inc's Price Over Earnings - Benzinga
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference - The AI Journal
Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Published on: 2025-11-20 01:52:12 - newser.com
Can Zoetis Inc. Class stock deliver double digit returns2025 Price Momentum & Short-Term Trading Alerts - newser.com
How supply shortages influence Zoetis Inc. Class stockJuly 2025 Technicals & Verified Momentum Stock Alerts - newser.com
Is Zoetis Inc. meeting your algorithmic filter criteria2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Published on: 2025-11-19 16:55:31 - newser.com
Is Zoetis Inc. Class stock a buy on weakness2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
Why Zoetis Inc. Class stock is a strong analyst pickTrade Risk Assessment & Growth Focused Entry Point Reports - newser.com
Technical signs of recovery in Zoetis Inc.Gap Up & Low Risk Entry Point Guides - newser.com
Is Zoetis Inc. Class stock cheap by valuation metricsPortfolio Performance Report & Safe Capital Growth Plans - newser.com
Zoetis to Host Innovation Webcast - The Globe and Mail
How big funds are accumulating Zoetis Inc. (ZOE) stock2025 Price Targets & AI Enhanced Trading Signals - newser.com
Published on: 2025-11-19 02:42:09 - newser.com
Can Zoetis Inc. stock hit record highs againJuly 2025 Trends & Low Risk Growth Stock Ideas - newser.com
Candlestick signals on Zoetis Inc. stock today2025 Growth vs Value & Technical Pattern Based Buy Signals - newser.com
Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News - GuruFocus
조에티스 (ZTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
0.20%
자본화:
|
볼륨(24시간):